227 391

Cited 2 times in

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea

DC Field Value Language
dc.contributor.author이병완-
dc.date.accessioned2019-12-18T00:37:45Z-
dc.date.available2019-12-18T00:37:45Z-
dc.date.issued2019-
dc.identifier.issn2233-6079-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173149-
dc.description.abstractBACKGROUND: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM). METHODS: This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia. RESULTS: The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. -0.9±6.0 kg, P=0.011). CONCLUSION: The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Diabetes Association-
dc.relation.isPartOfDIABETES & METABOLISM JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYu Mi Kang-
dc.contributor.googleauthorChang Hee Jung-
dc.contributor.googleauthorSeung-Hwan Lee-
dc.contributor.googleauthorSang-Wook Kim-
dc.contributor.googleauthorKee-Ho Song-
dc.contributor.googleauthorSin Gon Kim-
dc.contributor.googleauthorJae Hyeon Kim-
dc.contributor.googleauthorYoung Min Cho-
dc.contributor.googleauthorTae Sun Park-
dc.contributor.googleauthorBon Jeong Ku-
dc.contributor.googleauthorGwanpyo Koh-
dc.contributor.googleauthorDol Mi Kim-
dc.contributor.googleauthorByung-Wan Lee-
dc.contributor.googleauthorJoong-Yeol Park-
dc.identifier.doi10.4093/dmj.2018.0092-
dc.contributor.localIdA02796-
dc.relation.journalcodeJ00720-
dc.identifier.eissn2233-6087-
dc.identifier.pmid31237133-
dc.subject.keywordDiabetes mellitus, type 2-
dc.subject.keywordInsulin glargine-
dc.subject.keywordSafety-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.affiliatedAuthor이병완-
dc.citation.volume43-
dc.citation.number4-
dc.citation.startPage432-
dc.citation.endPage446-
dc.identifier.bibliographicCitationDIABETES & METABOLISM JOURNAL, Vol.43(4) : 432-446, 2019-
dc.identifier.rimsid63955-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.